SCHEMBL3015907

SCHEMBL3015907

Cc1cc(S(=O)(=O)C2CCN(c3nc(-c4ccccc4)cs3)CC2)c(Cl)cc1Cl

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.54
MAPK1 P28482 2/20 0.54
MEN1 O00255 2/20 0.54
KMT2A Q03164 2/20 0.54
SMN1; SMN2 Q16637 6/20 0.47
AR P10275 3/20 0.47
TP53 P04637 1/20 0.47
ALOX15 P16050 1/20 0.47
HSD17B10 Q99714 1/20 0.47
RAB9A P51151 7/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
NPC1 O15118 5/20 0.45
MAPT P10636 4/20 0.45
CYP1A2 P05177 1/20 0.45
CYP2C9 P11712 1/20 0.45
CYP2C19 P33261 1/20 0.45
KDM4E B2RXH2 1/20 0.45
HTT P42858 1/20 0.45
RECQL P46063 1/20 0.45
FFAR2 O15552 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2998403 0.92 SMN1; SMN2 (0.49) LMNAMAPK1MEN1KMT2ASMN1; SMN2
SCHEMBL3018331 0.92 SMN1; SMN2 (0.53) LMNAMAPK1MEN1KMT2ASMN1; SMN2
SCHEMBL3018199 0.92 SMN1; SMN2 (0.48) LMNAMAPK1MEN1KMT2ASMN1; SMN2
SCHEMBL3008704 0.90 SMN1; SMN2 (0.45) LMNAMAPK1MEN1KMT2ASMN1; SMN2
SCHEMBL2997914 0.90 SMN1; SMN2 (0.46) LMNAMAPK1MEN1KMT2ASMN1; SMN2
SCHEMBL3015483 0.89 AR (0.53) LMNAMAPK1MEN1KMT2ASMN1; SMN2
SCHEMBL3007283 0.89 AR (0.43) LMNAMAPK1MEN1KMT2ASMN1; SMN2
SCHEMBL3011287 0.89 SMN1; SMN2 (0.42) LMNAMAPK1MEN1KMT2ASMN1; SMN2
SCHEMBL3019957 0.89 SMN1; SMN2 (0.42) LMNAMAPK1MEN1KMT2ASMN1; SMN2
SCHEMBL3018665 0.89 LMNA (0.46) LMNAMAPK1MEN1KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA LMNA 80/4885MAPK1 2767/4885MEN1 454/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.